Free Trial
NASDAQ:WHWK

Whitehawk Therapeutics 8/7/2025 Earnings Report

$1.62 -0.09 (-5.26%)
As of 04:00 PM Eastern

Whitehawk Therapeutics EPS Results

Actual EPS
-$0.76
Consensus EPS
$0.49
Beat/Miss
Missed by -$1.25
One Year Ago EPS
N/A

Whitehawk Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
$100.00 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Whitehawk Therapeutics Announcement Details

Quarter
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Whitehawk Therapeutics Earnings Headlines

But this $20 American company could control the secret
The "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMOLISHED Google's record using pure light particles instead of exotic superconductors. The secret? A revolutionary material that ONE American company is the first to commercially produce.
See More Whitehawk Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Whitehawk Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Whitehawk Therapeutics and other key companies, straight to your email.

About Whitehawk Therapeutics

Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.

View Whitehawk Therapeutics Profile

More Earnings Resources from MarketBeat